AI Summary
The FDA committee voted that patisiran is beneficial for ATTR cardiomyopathy, but its clinical significance is debated.
An FDA advisory committee voted 9 to 3 that the benefits of patisiran outweigh the risks for ATTR cardiomyopathy, but many questioned whether the benefit is clinically meaningful.
Medscape Medical News